Navigation Links
VetStem Biopharma Heavily Featured in Recent Documentary About Regenerative Medicine for Domestic and Wild Animals
Date:7/2/2019

Leading Regenerative Veterinary Medicine company, VetStem Biopharma, was recently featured in a new documentary entitled Animal Pharm: Where Beasts Meet Biotech. The film focuses on regenerative veterinary medicine as a means of improving the quality of life for domestic and wild animals. Animal Pharm was recently included in the Brentwood and Pacific Palisades International Film Festival in Los Angeles, California where it received the award for Best Nature and Animals Film.

The film heavily features VetStem and includes an interview with VetStem Founder and CEO Dr. Bob Harman. Dr. Harman explains that when he first conceived of and formed VetStem, he was called “crazy.” Over time however the thinking has evolved so that regenerative medicine is now regarded as a legitimate and valuable tool for veterinarians.

Animal Pharm also touches on the fact that advances made in regenerative veterinary medicine have begun to translate into the human medical field. Dr. Harman commented, “The film provides a great service to the public by providing legitimate education about cell therapy in the veterinary field and how this can assist the field of human stem cell therapy. Elliott and Barbara did a splendid job of producing and editing this film and I am proud that the film received such a prestigious award at the Brentwood and Pacific Palisades International Film Festival. I anticipate worldwide distribution of this great film.”

VetStem has been providing stem cell services for over 15 years for the treatment of orthopedic conditions in dogs, cats, and horses. VetStem holds exclusive licenses to a large portfolio of patents, including world-wide veterinary rights for the use of adipose-derived stem cells. In recent months, VetStem launched a human stem cell company, Personalized Stem Cells, Inc (PSC), which plans to begin human stem cell clinical trials in late 2019.

About VetStem Biopharma, Inc.
VetStem Biopharma is a veterinarian-lead Company that was formed in 2002 to bring regenerative medicine to the profession. This privately held biopharmaceutical enterprise, based near San Diego, California, currently offers veterinarians an autologous stem cell processing service (from patients’ own fat tissue) among other regenerative modalities. With a unique expertise acquired over the past 15 years and 17,000 treatments by veterinarians for joint, tendon or ligament issues, VetStem has made regenerative medicine applications a therapeutic reality. The VetStem team is focused on developing new clinically practical and affordable veterinary solutions that leverage the natural restorative abilities present in all living creatures. In addition to its own portfolio of patents, VetStem holds exclusive global veterinary licenses to a large portfolio of issued patents in the field of regenerative medicine.

Read the full story at https://www.prweb.com/releases/vetstem_biopharma_heavily_featured_in_recent_documentary_about_regenerative_medicine_for_domestic_and_wild_animals/prweb16415753.htm.


'/>"/>
Source: PRWeb
Copyright©2019 Vocus, Inc.
All rights reserved


Related biology technology :

1. Vet-Stem, Inc. Meets New Milestones and Changes Name to VetStem Biopharma
2. VetStem Biopharma -Regenerative Cell Therapy has processed over 11,000 samples
3. Leading Regenerative Veterinary Medicine Company, VetStem Biopharma announces the addition of Dr Jeffrey Schaffer as the Director of Veterinary Professional Services.
4. West Coast Bird Dog Champion Wins US Bird Dog Association Western States National Flushing Champion with the help of Stem Cell Therapy by VetStem.
5. Leading Regenerative Veterinary Medicine Company, VetStem Biopharma, Announces the Addition of Dr Ross Rich as the Director of Clinical Development
6. VetStem Biopharma & Veterinary Growth Partners Join Forces to Increase Member Veterinary Hospital Revenue Through Cutting Edge Medical Offering
7. VetStem Biopharma, Proudly Announces a New Long Term Partnership with VCA West Los Angeles in Support of Stem Cell Therapy Training and Clinical Opportunities.
8. VetStem Biopharma, proudly announces a new long term partnership with VCA Emergency Animal Hospital & Referral Center.
9. VetStem Biopharma weekly veterinary continuing education classes and GMP manufacturing facility tour
10. VetStem Biopharma Successfully Completes Large Milestone Efficacy Study for its Flagship Canine Osteoarthritis Stem Cell Product
11. VetStem Biopharma, Inc. Founder and CEO, Dr. Robert Harman, to be a Guest Speaker at MSC 2015 Adult Stem Cell Therapy & Regenerative Medicine Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2020)... ... May 21, 2020 , ... ... trials will cause long-term harm , Contrary to conventional wisdom that says the ... finds many companies will emerge from the pandemic commercially weaker, dealing with ...
(Date:5/21/2020)... , ... May 20, 2020 , ... ... of Simon Prakash, who will serve as the company’s executive vice president of ... time when Exo is disrupting the medical imaging space, bringing more than 24 ...
(Date:5/15/2020)... ... May 14, 2020 , ... This new service offers ... the most pressing questions answered quickly as the need arises. Lachman’s OnCall SMEs have ... advice at affordable rates. , Lachman OnCall™ SMEs are available normal business hours ...
(Date:5/14/2020)... ... May 12, 2020 , ... NanoString ... bringing together thousands of industry leaders, clinicians, research scientists, medical professionals and academics ... Carl June, MD, Director of the Center for Cellular Immunotherapies at the Perelman ...
Breaking Biology Technology:
(Date:6/5/2020)... ... 04, 2020 , ... Greffex, a pioneering vaccine and gene therapy company based ... understands the need for a global perspective to make an impact in a post ... will serve as an independent, director of the company. , “The Greffex board is ...
(Date:5/28/2020)... ... May 27, 2020 , ... Today bioinformatics leader ... that uniquely combines lab testing insights and hc1’s exclusive Local Risk Index in ... and safety of employees returning to the workplace. , “Some of the best ...
(Date:5/25/2020)... ... 22, 2020 , ... Oxford Nanopore Technologies is in advanced development of a ... causes COVID-19. , The LamPORE assay is designed to be rapid, low ... large numbers of samples. Hardware and reagents sit outside current, squeezed supply chains ...
Breaking Biology News(10 mins):